Chemosensitivity of human malignant glioma: Modulation by p53 gene transfer

Journal of Neuro-Oncology

Volumn 39, Issue 1, 1998, Pages 19-32

  Trepel, Martin ^a   Groscurth, Peter ^b   Malipiero, Ursula ^c   Gulbins, Erich ^a   Dichgans, Johannes ^a   Weller, Michael ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Apoptosis; Chemoresistance; Gene therapy; P53; Tumor suppressor gene

Indexed keywords

CARMUSTINE; CYTARABINE; CYTOTOXIC AGENT; DOXORUBICIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; TENIPOSIDE; VINCRISTINE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; GENE MUTATION; GENE THERAPY; GENE TRANSFER; GLIOBLASTOMA; GROWTH DISORDER; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

EID: 0031689575     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005910323338     Document Type: Article

References (57)

1. Fine HA: The basis for current treatment recommendations for malignant gliomas. J Ncuro-oncol 20: 111-120, 1994
2. Whittle IR: Management of primary malignant brain tumours. J Ncurol Neurosurg Psychiatry 60; 2-5,1996
3. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblurn M, Cavanee W, Vogelstein B: Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature 355: 846-847, 1993
4. Louis DN, Von Deimling A, Chung RY, Rubio MR Whaley JM, Eibl RH, Ohgaki H, Wicstler OD, Thor AD, Seixinger BR: Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 52: 31-38, 1993
5. Van Meir EG, Kikuchi T, Tada M, Li H, Discrens AC, Wojcik BH, Huang H, Fricdmann T, de Tribolet N, Cavenee WK: Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 54: 649-652, 1994
6. Van Meyel DJ, Ramsay DA, Casson AG, Keeney M, Chambers AF, Cairncross JG: p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression. J Natl Cancer Inst 86: 1011-1017, 1994
7. Bögler O, Huang HJS, Kleihues P, Cavenee WK: The p53 gene and its role in human brain tumors. Glia 15: 308-327, 1995
8. Ozbun MA, Butel JS: Tumor suppressor p53 mutations and breast cancer: a critical analysis. Adv Cancer Res 66:71-141, 1995
9. El-Deiry WS, Harper JW, O'Connor PM, Velculcsco VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B: WAF1/CIP1 is induced in p53 mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994
10. Smith ML, Chen IT, Zhan O, Bae I, Chcn CY, Gilmer TM, Kastan MB, O'Connor PM, Fornace AJ; Interaction of the p53 regulated protein GADD45 with proliferating cell nuclear antigen. Science 266: 1376-1380, 1994
11. Miyashita T, Harigai M, Hanada M, Reed JC: Identification of p53-dependent negative response element in the bcl-2 gene. Cancer Res 54: 3131-3135, 1994
12. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805, 1994
13. Miyashita T, Reed JC; Tumor suppressor p53 is a direct transcriptional activator of the human bar gene. Cell 80: 293-299, 1995
14. Barak Y, Juven T, Haffner R, Oren M: MDM-2 expression is induced by wild type p53 activity. EMBO J 12: 461-468, 1995
15. Shiio Y, Yamamoto T, Yamaguchi N: Negative regulation of Rb expression by the p53 gene product. Proc Natl Acad Sci USA 89: 5206-5210, 1992
16. Caelles C, Helmberg A, Karin M: p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370: 220-223, 1994
17. Haupt Y, Rowan S, Shaulian E, Vousdcn KH, Oren M: Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev 9: 2170-2183, 1995
18. Sidransky D, Hollstein M: Clinical implications of the p53 gene. Ann Rev Med 47: 285-301, 1996
19. Neubauer A, Thiede C, Huhn D, Wittig B:p53 and induction of apoptosis as a target for anticancer therapy. Leukemia 10: S2-S4, 1996
20. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimehi A, Oren M: Wild-type p53 induces apoptosis of mycloid leukaemic cells that is inhibited by interleukin-6. Nature 352: 345-347, 1991
21. Vikhanskaya F, Erba E, D'lncalci M, Broggini M: Introduction of wild-type p53 in a human ovarian cancer cell line NO2-TYR expressing endogenous p53. Nucleic Acids Res 22: 1012-1017, 1994
22. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, Connell-Crowley L, Elledge SJ, Zhang WW. Harper JW, Thompson TC: In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55: 5151-5155, 1995
23. Yang B, Eshleman JR, Berger NA, Markowitz SD: Wildtype p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res 2: 1649-1657, 1996
24. Mercer WE. Shields MT, Amin M, Sauve GJ, Apella E, Romano JW, Ulrich SJ: Negative growth regulation in aglioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci USA 87: 6166-6170,1990
25. Mcrzak A, Raynal S, Roger JP, Lawrence D, Pilkington GF: Human wild-type p53 inhibits cell proliferation and elicits dramatic morphological changes in human glioma cell lines in vitro. J Neurol Sci 127: 125-133, 1994
26. Van Meir EG, Roemer K, Diserens AC, Kikuchi T, Rempel SA, Haas M, Huang S, Friedmann T, de Tribolet N, Cavenee WK: Single cell monitoring of growth arrest and morphological changes induced by transfer of wild type p53 alleles to glioblastoma cells. Proc Natl Acad Sci USA 92: 1008-1012, 1995
27. Badic B. Drazan KE, Kramar Mil, Shaked A, Black KL: Adenovirus-mediated p53 gene delivery inhibits 91. glioma growth in rats. Neurol Res 17: 209-216, 1995
28. Gomez-Manzano C, Fueyo J, Kyritsis AP, Steck PA, Roth JA, McDonnell TJ, Steck KD, Levin VA, Yung WKA: Adenovirus-mediated transfer of p53 gene produces rapid and generalised death of human glioma cells via apoptosis. Cancer Res 56: 694-699, 1996
29. Lowe SW, Ruley JE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993
30. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T: p53 is required for radiation induced apoptosis in mouse thymocytes. Nature 362: 847-849, 1993
31. Russell SJ, Ye YW, Waber PG, Shuford M, Schold SC, Nisen PD: p53 mutations. 06-alkylguanine DNA alkyltransferase activity, and sensitivity to procarbazine in human brain tumors. Cancer 75: 1339-1342, 1995
32. Malcomson RDG, Oren M, Wyllie AH, Harrison DJ: p53-independent death and p53-induced protection against apoptosis in fibroblasts treated with chemotherapeutic drugs. Br J Cancer 72: 952-957, 1995
33. Vikhanskaya F, D'Incalci M, Broggini M: Decreased cytotoxic effects of doxorubicin in a human ovarian cancer cell line expressing wild-type p53 and wafl/cipl genes. Int J Cancer 61: 397-401, 1995
34. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, Young LS: The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and bcl-2. Oncogene 11: 1217-1228, 1995
35. Hawkins DS, Demers GW, Galloway DA: Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56: 892-898, 1996
36. Blagosklonny MV, El-Deiry WS: In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. Int J Cancer 67: 386-392, 1996
37. Spitz FR, Nguyen D, Scibber JM, Meyn RE, Cristiano RJ, Roth JA: Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 2: 1639-1647, 1996
38. Yang B, Stambrook PJ, Markowitz SD: Wild-type p53 demonstrates functional dominance in a human colon carcinoma cell line in which it induces reversible growth arrest. Clin Cancer Res 2: 1639-1647, 1996
39. Fan S, El-Deiry WS, Bae I, Freeman J, Jondlc D, Bhatia K, Fornace AJ, Magrath I, Kohn KW, O'Connor PM: p53 gene mutations arc associated with decreased sensitivity of hu man lymphoma cells to DNA damaging agents, Cancer Res 54: 5824-5830, 1994
40. Petty RD, Cree IA, Sutherland LA, Hunter EM, Lane DP, Preece PE, Andreotti PE: Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity. Biochem Biophys Res Commun 199: 264-270, 1994
41. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Grala R, Kris M, Dmitrovski E; Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 55: 5038-5042, 1995
42. Brachman DG, Beckett M, Graves D, Haraf D, Vokes E, Weichselbaum RR: p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res 53: 3667-3669, 1993
43. Jacquemier J, Pennault-Llorea F, Viens F, Houvenaeghel G, Hanssoun J, Torrente M. Adelaide J, Birnbaum D: Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression. Anticancer Res 14: 2773-2778, 1994
44. Michalowitz D, Halevy O, Oren M: Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62: 671-680, 1990
45. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A: Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest 94: 954-964, 1994
46. Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A: Protooncogene bcl-2 gene transfer abrogates Fas-APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 95: 2633-2643, 1995
47. Ryan JJ, Prochownik E, Gottlieb CA, Apel IJ, Merino R, Nunez G, Clarke MF: c-myc and bcl-2 modulate p53-function by altering p53 subcellular trafficking during the cell cycle. Proc Natl Acad Sci USA 91: 5878-5882, 1994
48. 2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression. Eur J Immunol 24: 1293-1298, 1994
49. Weller M, Trepel M. Grimmel C, Schabet M, Bremen D, Krajewski S, Reed JC: Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53. Neurol Kes 19: 459-470, 1997
50. Hudson JM, Frade R, Bar-Eli M: Wild-type p53 regulates its own transcription in a cell-type specific manner. DNA Cell Biol 14: 759-766, 1995
51. Mosner J. Muminenbrauer T, Bauer C, Sczakiel G, Grosse F, Deppert W: Negative feedback regulation of wild-type p53 biosynthesis. EMBO J 14: 4442-4449, 1995
52. Wu X, Bayle JH, Olson D, Levine AJ: The p53-mdm-2 autoregulatory feedback loop. Genes Develop 1: 1126-1132, 1993
53. Zhan Q, Fan S, Bac I, Guillouf C, Lieberman DA, O'Connor PA, Fornace AJ; Induction of bax by genotoxic stress in hu man cells correlates with normal p53 status and apoptosis, Oncogcnc 9: 3743-3751, 1994
54. Lee JM, Bernstein A; Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Met Rev 14: 149-161, 1995
55. Harvey M, Vogel H, Morris D, Bradley A, Bernstein A, Donehower LA: A mutant p53 transgene accelerates tumor development in lieterozygous but not nullizygous p53-deficient mice. Nat Gen 9: 305-311, 1995
56. Kondo S, Barnett GH, Hara H, Morimura T, Takeuchi J: MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogcnc 10: 2001-2006, 1995
57. Labrecque S, Matlashewski GJ: Viability of wild type p53-containing and p53-deficient tumor cells following anticancer treatment: the use of human papillomavirus E6 to target p53. Oncogene 11: 387-392, 1995